Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07204340 · ClinicalTrials.gov registry record · Phase 1
TLN-372 in Advanced KRAS Mutant Solid Tumors
A Phase 1 study of KRAS Mutant Solid Tumors, sponsored by Treeline Biosciences.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 240
- Enrollment target
- 10
- Study locations
NCT07204340: Recruiting Phase 1 study of KRAS Mutant Solid Tumors, sponsored by Treeline Biosciences.
NCT07204340 is a Phase 1 study of KRAS Mutant Solid Tumors that is actively recruiting participants, run by Treeline Biosciences. The registered enrollment target is 240 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (300% higher). The trial reports 10 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07204340, a Phase 1 study of KRAS Mutant Solid Tumors, is actively recruiting participants, sponsored by Treeline Biosciences.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 240 participants
- Enrollment target
- 10
- Study locations
Study Summary
The primary purpose of this study is to evaluate the safety, pharmacokinetics, and anti-tumor activity of TLN-372 as a single agent and in combination with other anti-tumor agents, in patients with advanced KRAS mutant solid tumors
Conditions Studied
Interventions
- DRUG TLN-372
- DRUG TLN-372 in combination with cetuximab
- DRUG TLN-372 in combination with pembrolizumab
Study Locations (10)
Alabama
- University of Alabama at Birmingham - Birmingham
Massachusetts
- Dana-Farber Cancer Institute - Boston
Michigan
- START Midwest - Grand Rapids
Missouri
- Washington University Medical Campus - St Louis
New York
- Memorial Sloan Kettering Cancer Center - New York
Tennessee
- Sarah Cannon Research Institute - Nashville
Victoria
- Peter MacCallum Cancer Centre - Melbourne
Western Australia
- Linear Clinical Research - Perth
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2025-09-29 |
| Est. Completion | 2032-04-01 |
| Phase | Phase 1 |
What NCT07204340 shows while recruiting
NCT07204340 is an interventional study that assigns participants to a tested intervention. The registered 240 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (300% higher).
The record links to 1 condition, with KRAS Mutant Solid Tumors appearing as the primary indexed condition, and to 3 interventions - of which TLN-372 is the first listed.
NCT07204340 lists 10 locations in 10 states (Alabama, Massachusetts, Michigan).
Frequently Asked Questions
What is clinical trial NCT07204340 about?
NCT07204340 is a clinical study titled "TLN-372 in Advanced KRAS Mutant Solid Tumors". The primary purpose of this study is to evaluate the safety, pharmacokinetics, and anti-tumor activity of TLN-372 as a single agent and in combination with other anti-tumor agents, in patients with advanced KRAS mutant solid tumors
What is the current status of trial NCT07204340?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 240 participants. The study started on 2025-09-29. Estimated completion is 2032-04-01.
What conditions does trial NCT07204340 study?
This clinical trial studies the following conditions: KRAS Mutant Solid Tumors.
What interventions are being tested in trial NCT07204340?
The interventions under investigation include: TLN-372 (DRUG), TLN-372 in combination with cetuximab (DRUG), TLN-372 in combination with pembrolizumab (DRUG).
Who is sponsoring clinical trial NCT07204340?
This trial is sponsored by Treeline Biosciences, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07204340 being conducted?
This trial has 10 study locations across Alabama, Massachusetts, Michigan, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07204340's enrollment target sits among peer trials
240 198th of 2000 higher than 1,789 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI